Utilization and relative value of breast cancer adjuvant chemotherapy regimens in the community

被引：0
|
作者：
Patt, D. A.
Espirito, J. L.
Turnwald, B.
Hoverman, J. R.
Neubauer, M. A.
Cartwright, T. H.
Brooks, B. D.
Busby, L. T.
Sitarik, M. A.
Kolodziej, M. A.
Ginsburg, A. L.
Sheth, S.
Garey, J. S.
Clayton, M.
Nelson, G. C.
Anderson, R. W.
Beveridge, R. A.
机构：
[1] US Oncol, The Woodlands, TX USA
[2] US Oncol, Texas Oncol, The Woodlands, TX USA
[3] US Oncol, Kansas City Canc Ctr, The Woodlands, TX USA
[4] Ocala Oncol, Ocala, FL USA
[5] US Oncol, Rocky Mt Canc Ctr, Boulder, CO USA
[6] US Oncol, New York Hematol Oncol, Albany, NY USA
[7] US Oncol Pathways Task Force, The Woodlands, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e16595
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16595
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Utilization of pegfilgrastim in adjuvant chemotherapy regimens for breast cancer in the community.
    Patt, D. A.
    Espirito, J. L.
    Turnwald, B.
    Hoverman, J. R.
    Neubauer, M. A.
    Busby, L. T.
    Broolos, B. D.
    Kolodziej, M. A.
    Anderson, R. W.
    Beveridge, R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
  • [2] Relative benefits of newer adjuvant chemotherapy regimens in luminal breast cancer subtypes
    Hart, Christopher D.
    Di Leo, Angelo
    BREAST, 2016, 27 : 189 - 189
  • [3] Primary and Secondary Pegfilgrastim Utilization in Adjuvant Chemotherapy for Breast Cancer in the Community.
    Patt, D. A.
    Espirito, J. L.
    Turnwald, B.
    Hoverman, J. R.
    Neubauer, M. A.
    Busby, L. T.
    Brooks, B. D.
    Kolodziej, M. A.
    Anderson, R. W.
    Beveridge, R. A.
    CANCER RESEARCH, 2011, 71
  • [4] Different adjuvant chemotherapy regimens in older breast cancer patients?
    Wildiers, H.
    Brain, E.
    ANNALS OF ONCOLOGY, 2015, 26 (04) : 613 - 615
  • [5] Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer
    Stover, Daniel G.
    Winer, Eric P.
    BREAST, 2015, 24 : S132 - S135
  • [6] Breast Cancer Survivorship Care Variations Between Adjuvant Chemotherapy Regimens
    Leal, Alexis D.
    Van Houten, Hay
    Sangaralingham, Lindsey
    Freedman, Rachel A.
    Jemal, Ahmedin
    Neuman, Heather B.
    Haddad, Tufia C.
    Mutter, Robert W.
    Keegan, Theresa H. M.
    Mougalian, Sarah S.
    Loprinzi, Charles L.
    Gross, Cary P.
    Shah, Nilay
    Ruddy, Kathryn J.
    CLINICAL BREAST CANCER, 2018, 18 (04) : E513 - E520
  • [7] Weight change during adjuvant chemotherapy regimens for breast cancer.
    Speck, R. M.
    DeMichele, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens
    Griggs, Jennifer J.
    Culakova, Eva
    Sorbero, Melony E. S.
    Poniewierski, Marek S.
    Wolff, Debra A.
    Crawford, Jeffrey
    Dale, David C.
    Lyman, Gary H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18) : 2522 - 2527
  • [9] Relative dose intensity reduction in breast cancer adjuvant chemotherapy
    Faustino, C.
    Afonso, N.
    Sousa, B.
    Espirito, Santo J.
    Rodrigues, H.
    CANCER RESEARCH, 2009, 69 (02) : 283S - 284S
  • [10] Adjuvant chemotherapy for luminal A breast cancer: a prospective study comparing two popular chemotherapy regimens
    Kader, Yasser Abdel
    El-Nahas, Tamer
    Sakr, Amr
    ONCOTARGETS AND THERAPY, 2013, 6 : 1073 - 1077
12345